Use of Intralesional Voriconazole for the Treatment of Cutaneous<i>Scedosporium apiospermum</i>Infection

Azofra, Mariola Moreno; Somovilla, José Luis Peña; Porras, Miguel Carrascosa; Carrillo, Laura Hurtado; Pérez, R. Daroca

doi:10.1086/653683

Cited by 18 publications

(11 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In vitro synergistic effects of azoles combined with echinocandins were reported by Cuenca–Estrellas et al. 1 Other studies demonstrated a profound synergistic effect of azole‐terbinafin combinations 3–32 . Therefore, in addition to terbinafin, MICA should be also taken into consideration as possible combination therapy option for Scedosporium infections, preferably in combination with VOR.…”

Section: Discussionmentioning

confidence: 85%

“…Our results show that in general, MICA had reasonable in vitro activity against all Pseudallescheria / Scedosporium species except S. prolificans (Table 2). Monotherapy using VOR has frequently been reported to be tolerated by patients and was successful in treatment of S. apiospermum infections 25–28 . MICA exerts antifungal activity via inhibition of (1,3)‐β‐d‐glucan synthase, 29 and therefore may enhance in combination therapy the fungicidal effect of other antifungal compounds targeting different cellular elements.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Infection and colonisation due to Scedosporium in Northern Spain. An in vitro antifungal susceptibility and molecular epidemiology study of 60 isolates

Lackner

Rezusta

Villuendas

et al. 2011

Mycoses

View full text Add to dashboard Cite

SummarySince the latest taxonomical changes in the genus Scedosporium by Gilgado et al. in 2010, no species-specific studies on epidemiology and antifungal susceptibility patterns (AFSP) have so far been published. This study aimed to provide qualitative epidemiological data of Scedosporium spp. isolated from cystic fibrosis (CF) patients and immunocompromised patients from Northern Spain. Isolates were identified by using amplified fragment length polymorphism (AFLP), and species-specific AFSP were generated for all currently available antifungal compounds. AFLP was a useful tool for identification to species-level and for the discrimination of inter-and intra-patient isolates. Scedosporium prolificans represents the most prevalent species in the respiratory tract of CF patients and immunocompromised patients in Northern-Spain, followed by Pseudallescheria boydii, P. apiosperma, and P. ellipsoidea. CF patients were exclusively colonised with either P. boydii or S. prolificans. Patients were colonised over years exclusively with isolates affiliated to one species, but some patients were colonised with multiple strains with different AFSP. The sum of those co-colonising strains in one patient, may appear in vitro and in vivo as a multi-resistant S. prolificans isolate, as strains are morphologically identical and might therefore be regarded as only one strain. A majority of Scedosporium strains (with exception of S. prolificans) were found susceptible for voriconazole and micafungin.

show abstract

Section: Discussionmentioning

confidence: 85%

Section: Discussionmentioning

confidence: 99%

Infection and colonisation due to Scedosporium in Northern Spain. An in vitro antifungal susceptibility and molecular epidemiology study of 60 isolates

Lackner

Rezusta

Villuendas

et al. 2011

Mycoses

View full text Add to dashboard Cite

show abstract

“…Voriconazole is a new-generation triazole with broad-spectrum antifungal activity against Aspergillus, fluconazole-resistant Candida, Fusarium and Scedosporium species [1,2]. Clinically, it is used to treat and prevent invasive fungal infections (IFIs).…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections

Wang¹,

Zhu²,

Sun³

et al. 2014

International Journal of Antimicrobial Agents

136

View full text Add to dashboard Cite

“…Voriconazole is currently the preferred therapy for invasive Aspergillus infection and other IFIs . The agent exhibits broad‐spectrum activity against many common yeast and mold species, as well as some emerging pathogens such as Scedosporium apiospermum and Fusarium species …”

mentioning

confidence: 99%

Risk Factors for Voriconazole-Associated Hepatotoxicity in Patients in the Intensive Care Unit

Wang

Xie

et al. 2016

Pharmacotherapy

View full text Add to dashboard Cite

show abstract

Use of Intralesional Voriconazole for the Treatment of CutaneousScedosporium apiospermumInfection

Cited by 18 publications

References 5 publications

Infection and colonisation due to Scedosporium in Northern Spain. An in vitro antifungal susceptibility and molecular epidemiology study of 60 isolates

Infection and colonisation due to Scedosporium in Northern Spain. An in vitro antifungal susceptibility and molecular epidemiology study of 60 isolates

Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections

Risk Factors for Voriconazole-Associated Hepatotoxicity in Patients in the Intensive Care Unit

Contact Info

Product

Resources

About